Iodopovidone pleurodesis does not effect thyroid function in normal adults

Yeginsu, Ali; Karamustafaoğlu, Yekta Altemur; Özuğurlu, Fikret; Etikán, Ílker

doi:10.1510/icvts.2007.154914

Cited by 27 publications

(23 citation statements)

References 1 publication

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…High concentrations of exogenous iodine are capable of diminishing thyroid hormone synthesis or induce thyrotoxicosis in susceptible individuals (22). However, Yeginsu et al (23) reported that the intrapleural administration of 100 mL of 2% iodopovidone did not affect thyroid hormone levels in humans. Although our study was conducted in an animal model, we did not find abnormal results in thyroid hormone levels, even in high concentrations.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of iodopovidone in an experimental pleurodesis model

Teixeira¹,

Vargas²,

Puka³

et al. 2013

Clinics

View full text Add to dashboard Cite

OBJECTIVES:Chemical pleurodesis is an important therapeutic tool to control recurrent malignant pleural effusion. Among the various sclerosing agents, iodopovidone is considered effective and safe. However, in a recent study, ocular changes were described after iodopovidone was used in recurrent pneumothorax. The aim of the study was to evaluate the efficacy and morbidity of iodopovidone pleurodesis in an experimental model.METHODS:New Zealand rabbits were submitted to intrapleural injection of iodopovidone at concentrations of 2%, 4% and 10%. Biochemical (lactic dehydrogenase, proteins, triiodothyronine, free thyroxine, urea and creatinine) and immunological (Interleukin-8 [IL-8], VEGF and TGFβ) parameters were measured in the pleural fluid and blood. After 1, 3, 7, 14 and 28 days, groups of animals were euthanized, and macro- (pleura) and microscopic (pleura and retina) analyses were performed.RESULTS:An early pleural inflammatory response with low systemic repercussion was observed without corresponding changes in thyroid or renal function. The higher concentrations (4% and 10%) correlated with greater initial exudation, and maximum pleural thickening was observed after 28 days. No changes were observed in the retinal pigment epithelium of the rabbits.CONCLUSION:Iodopovidone is considered to be an effective and safe sclerosing agent in this animal model. However, its efficacy, tolerance and safety in humans should be further evaluated.

show abstract

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of iodopovidone in an experimental pleurodesis model

Teixeira¹,

Vargas²,

Puka³

et al. 2013

Clinics

View full text Add to dashboard Cite

show abstract

“…Empyema is also a rarely seen complication, [14] and visual loss after iodopovidone pleurodesis was reported by Wagenfeld et al [15] Although it has been reported that topical iodopovidone applications or the use of iodopovidone-based contrast agents may cause transient thyroid dysfunction, especially in infants, the study of Yeginsu et al [16] determined that the intrapleural administration of iodopovidone did not affect thyroid hormone levels. [17] In our study, we did not observe any signs or symptoms of hypothyroidism or hyperthyroidism in the patients during the follow-up period.…”

Section: Discussionmentioning

confidence: 99%

Iodopovidone pleurodesis in the treatment of refractory pleural effusions

Yazkan¹

2013

Turk Gogus Kalp Dama

View full text Add to dashboard Cite

Amaç: Bu çalışmada refrakter plevral efüzyonlu hastalarda iodopovidon plörodezinin etkinliği değerlendi-rildi. Ça lış ma pla nı: Mart 2009 -Nisan 2012 tarihleri arasında refrakter plevral efüzyonlu 43 hastada (34 erkek, 9 kadın; ort. yaş 65.6±9.8 yıl; dağılım 37-79 yıl) iodopovidon plörodez tedavi amacı ile kullanıldı. Plevral efüzyon nedeni 31 hastada malignite ve 12 hastada kalp yetmezliği idi. İodopovidon (20 mL 10%'luk artı 80 mL %0.9 NaCl) göğüs tüpünden verildi. Tüp klempe edilmeksizin göğüs seviyesinden 60 cm yukarıda tutuldu. Drenaj miktarı 50 ml/güne gerilediğinde tüp çıkarıldı. Bul gu lar: İodopovidon irigasyonu ile malign plevral efüzyonlu hastalarda günlük drenaj miktarında 574.9±169.0 ml'den 71.7±25.9 mL'ye anlamlı bir düşüş sağ-landı (p=0.000), kalp yetmezliği olan hastalarda da günlük drenaj miktarında 588.9±138.4 mL'den 63.5±12.5 mL'ye anlamlı bir düşüş sağlandı (p<0.001). İşleme ait hiçbir klinik yan etki gözlenmedi. So nuç: İnatçı plevral efüzyonu olan hastalarda iodopovidon plörodezinin etkinliği gösterilmiştir. Bu ajanın göğüs tüpünü klemplemeden kullanılması güvenli, ucuz ve etkindir.Anah tar söz cük ler: İodopovidon; plevra; plevral efüzyon; plöro-dez; tedavi.

show abstract

“…Thyroid function is a concern when using iodine therapies and whether iodopovidone pleurodesis interferes with this function is still a matter of debate [20,27]. Yeginsu et al [27] analyzed thyroid hormones 24 and 72 h after pleurodesis with iodopovidone in 12 patients with MPE.…”

Section: Discussionmentioning

confidence: 99%

“…Yeginsu et al [27] analyzed thyroid hormones 24 and 72 h after pleurodesis with iodopovidone in 12 patients with MPE. They found no difference in these hormone levels over time.…”

Section: Discussionmentioning

confidence: 99%

Safety Profile of the Use of Iodopovidone for Pleurodesis in Patients with Malignant Pleural Effusion

Neto¹,

Terra²,

Teixeira³

et al. 2015

Respiration

View full text Add to dashboard Cite

Background: Iodopovidone is an alternative agent used to promote pleurodesis in patients with malignant pleural effusion (MPE). However, safety is a concern, and many authors still reject its use. Objectives: Our main objective is to describe the occurrence of common and severe adverse events after pleurodesis with two different doses of iodopovidone in patients with MPE. Our secondary objective is to evaluate dose dependency, efficacy, quality of life, and systemic inflammation. Methods: We conducted a double-blind, randomized clinical trial including patients with recurrent MPE. Patients underwent chest tube insertion and were randomized into two groups according to the doses of iodopovidone: group 1 received 1% iodopovidone, and group 2 received 2% iodopovidone. During follow-up, adverse events, inflammatory markers, quality of life, and imaging exams were systematically evaluated and registered. Results: Sixty patients were analyzed (55 females, 5 males, median age 55.9 years). Overall, 227 adverse events possibly related to pleurodesis were registered, including 47 serious adverse events (in 34 patients). Pleuritic pain and hypertensive peaks were the most frequently observed serious adverse events (11 and 10 episodes, respectively). Grade 3/4 metabolic events such as hyponatremia and an increase in alkaline phosphatase, AST and ALT levels were also common. C-reactive protein (CRP) levels increased substantially and peaked 48 h after pleurodesis. No difference was observed between groups with regard to adverse events, CRP levels, efficacy, or quality of life. Conclusions: Adverse events after iodopovidone pleurodesis in patients with MPE are common and similar in the two doses studied.

show abstract

Iodopovidone pleurodesis does not effect thyroid function in normal adults

Cited by 27 publications

References 1 publication

Effectiveness and safety of iodopovidone in an experimental pleurodesis model

Effectiveness and safety of iodopovidone in an experimental pleurodesis model

Iodopovidone pleurodesis in the treatment of refractory pleural effusions

Safety Profile of the Use of Iodopovidone for Pleurodesis in Patients with Malignant Pleural Effusion

Contact Info

Product

Resources

About